Pharmaceutical - Markets & Marketing, Nephrology and Hepatology

Filter

Popular Filters

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

29-01-2014

After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

Chronic kidney disease market to witness slight decline by 2017

Chronic kidney disease market to witness slight decline by 2017

12-11-2013

The value of the chronic kidney disease market could drop 2.5% between 2012 and 2017 due to the loss…

EuropeFinancialGenzymeMarkets & MarketingNephrology and HepatologyPharmaceuticalRenagelRenvelaUSAZemplar Capsules

Alfa Wassermann and Norgine's Targaxan gets first European launch, in UK

28-01-2013

Following recent European Union approval (The Pharma Letter December 9, 2012), Netherlands-based Norgine…

Alfa WassermannEuropeMarkets & MarketingNephrology and HepatologyNorginePharmaceuticalTargaxanXifaxan

Japan launches for Lotriga and Argamate

11-01-2013

Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

Takeda and Affymax in supply deal for Omontys injection with US Renal Care

10-08-2012

Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) and Affymax (Nasdaq: AFFY) have said that…

AffymaxMarkets & MarketingNephrology and HepatologyNorth AmericaOmontysPharmaceuticalTakeda Pharmaceuticals

Astellas debuts Kiklin capsules, for hyperphosphatemia, in Japan

26-06-2012

Japanese drug major Astellas Pharma (TYO: 4503) yesterday launched Kiklin capsules 250mg (bixalomar)…

Asia-PacificAstellas PharmaKiklinMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Pharma scrambling to expand gout treatment market

23-05-2012

Joint pain caused by gout may be on its way out, as the ever-expanding market encourages the discovery…

Anti-Arthritics/RheumaticsMarkets & MarketingNephrology and HepatologyPharmaceuticalResearch

BTG debuts Voraxaze in the USA

01-05-2012

The US subsidiary of the UK-based BTG (LSE: BGC) yesterday announced the launch of Voraxaze (glucarpidase)…

ASD HealthcareBTGMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalVoraxaze

Astellas and Sanwa to co-promote kidney disease drugs in Japan

21-02-2012

Japanese drug major Astellas Pharma (TYO: 4503) yesterday revealed that it has linked up with fellow…

ArgamateAsia-PacificAstellas PharmabixalomerMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Robust growth forecast for renal cell carcinoma market

11-12-2011

The renal cell carcinoma drug market will experience robust 3.7% annual growth from 2010 to 2020 in the…

axitinibdovitinibGlaxoSmithKlineMarkets & MarketingNephrology and HepatologyNovartisOncologyPfizerPharmaceuticalSutentVotrient

Back to top